Quantum Private Wealth LLC Has $1.06 Million Position in Exact Sciences Corporation $EXAS

Quantum Private Wealth LLC lessened its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 52.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,986 shares of the medical research company’s stock after selling 22,393 shares during the quarter. Quantum Private Wealth LLC’s holdings in Exact Sciences were worth $1,062,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Great Lakes Advisors LLC boosted its position in shares of Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 178 shares in the last quarter. Nissay Asset Management Corp Japan ADV lifted its stake in Exact Sciences by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock worth $971,000 after purchasing an additional 187 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Exact Sciences by 0.4% during the second quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock valued at $3,127,000 after purchasing an additional 217 shares in the last quarter. IFP Advisors Inc boosted its holdings in Exact Sciences by 6.5% during the second quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 273 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Exact Sciences by 37.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 275 shares during the period. 88.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EXAS has been the subject of several analyst reports. Piper Sandler raised their target price on Exact Sciences from $70.00 to $80.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Evercore ISI lifted their price objective on Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Cowen restated a “buy” rating on shares of Exact Sciences in a research note on Tuesday, November 4th. Leerink Partnrs cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, Baird R W lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $79.38.

Exact Sciences Stock Up 0.2%

Shares of NASDAQ:EXAS opened at $100.90 on Friday. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. The firm has a market cap of $19.12 billion, a P/E ratio of -18.58, a P/E/G ratio of 5.56 and a beta of 1.34. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $101.87. The company’s 50-day moving average price is $62.85 and its two-hundred day moving average price is $55.45.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. The company’s revenue was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In related news, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the transaction, the director owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brian Baranick sold 2,858 shares of Exact Sciences stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the sale, the executive vice president owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. The trade was a 11.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 9,858 shares of company stock worth $695,289. Insiders own 1.20% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.